Thursday 10 September 2026

One To Watch

Orbis Medicines

A Danish biotechnology company developing oral macrocycle drugs.

Company Overview

Want to Update your Company's Profile?


Latest Orbis Medicines News

The Pharma Letter Podcast — Episode 39 — Orbis CEO on turning biologics into pills
20 August 2026
Orbis fundraise shows growing interest in macrocyclic drugs
6 February 2025
Orbis Medicines’ Series A to fund pioneering oral macrocycle drugs
6 January 2025
Novo Holdings announces launch of new company Orbis Medicines
29 February 2024
More Orbis Medicines news >


Today's issue

US generic and biosimilar meds save $496B in just 1 year
Generics
US generic and biosimilar meds save $496B in just 1 year
10 September 2026
Biotechnology
NICE backs Darzalex-based quadruplet for newly-diagnosed myeloma, J&J's second blood cancer win in a week
10 September 2026
Biotechnology
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
10 September 2026
Biotechnology
Evommune's EVO756 misses primary endpoint in atopic dermatitis Phase IIb
10 September 2026
Biotechnology
FDA accepts Roche’s Enspryng sBLA for MOGAD
10 September 2026
Biotechnology
Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody
10 September 2026
Biotechnology
Alchemab Therapeutics expands leadership team
10 September 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze